A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
Latest Information Update: 23 Jan 2024
At a glance
- Drugs DT 2216 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Dialectic Therapeutics
- 16 Jan 2024 Status changed from recruiting to completed.
- 05 Sep 2023 Planned End Date changed from 15 Jun 2023 to 15 Mar 2024.
- 05 Sep 2023 Planned primary completion date changed from 30 Apr 2023 to 30 Dec 2023.